Method and system for isotope production

Abstract

A method for producing Pb-212 and Ac-225 isotopes is disclosed. The method includes irradiating a Ra-226-containing target with charged particles and / or photons to produce at least Ac-225 and Ac-224 isotopes. The method further includes, after a cooling period, applying chromatography to separate actinium from a remaining fraction containing radium. The method also includes, after a first additional waiting period, applying extraction chromatography using a resin having 18-crown-6 ether or an equivalent of 18-crown-6 ether as an extractant in HNO and / or HCl to separate Pb from a remaining fraction containing radium.

Description

[Technical Field]

[0001] The present invention relates to the field of nuclear medicine science. More specifically, the present invention relates to methods and systems for the production of isotopes and the isotopes so obtained. [Background technology]

[0002] It is known that Ac-225 can be used in clinical applications in nuclear medicine, for example, for the radiation treatment of malignant tumors. One method of producing Ac-225 is by proton irradiation of a Ra-226 target (e.g., RaCl2). When Ra-226 (T1 / 2: 1600 years) is irradiated with low-energy (10-25 MeV) protons, Ac-225 (T1 / 2: 10 days) is formed in the Ra-226(p,2n)Ac-225 nuclear reaction. At approximately 14 MeV, the threshold energy for the (p,3n) reaction is reached, resulting in the production of Ac-224 (T1 / 2: 2.9 hours), which rapidly decays to Ra-224 (T1 / 2: 3.66 days).

[0003] After irradiation, Ac-225 must be purified from Ra and its progeny (e.g., Pb, Po, and Bi) before use.

[0004] Nevertheless, Pb-212 (T1 / 2: 10.64 hours), which decays to Bi-212, is also a suitable target isotope for targeted alpha therapy (TAT). Due to differences in half-life and a shorter decay chain, Pb-212 is not considered a direct competitor of Ac-225, but rather a competitor of At-211 (T1 / 2: 7.22 hours).

[0005] Because the sources for producing medical isotopes are limited, there is a need for efficient methods and systems for producing medical isotopes. Summary of the Invention

[0006] It is an object of embodiments of the present invention to provide a good system and method for producing medical isotopes, as well as the isotopes so obtained.

[0007] An advantage of embodiments of the present invention is that the associated production of Pb-212 isotope is obtained as a by-product of the production of Ac-225 isotope, which is an important isotope for targeted alpha therapy. Pb-212 isotope is also an important isotope for targeted alpha therapy in its own right. An advantage of embodiments of the present invention is that the production of Ac-224 during the production of Ac-225 isotope is advantageously used to derive Pb-212 isotope therefrom, rather than ignoring this fraction and considering it a negative by-product.

[0008] The present invention relates to a method for producing Pb-212 and Ac-225 isotopes, the method comprising: irradiating a Ra-226 containing target with charged particles and / or photons to produce at least Ac-225 and Ac-224 isotopes; After a cooling period, applying chromatography to separate actinium from the remaining fraction containing radium; and After a first further waiting period, this involves applying extraction chromatography using a resin with 18-crown-6 ether or an equivalent of 18-crown-6 ether as extractant in HNO3 and / or HCl to separate Pb from the remaining fraction containing radium.

[0009] Separation of actinium from the remaining fraction containing radium can be carried out by applying extraction chromatography.

[0010] Alternatively, separation of actinium from the remaining fraction containing radium can be carried out by applying ion exchange chromatography using a cation exchange column, in which the difference in charge between Ra(2+) and Ac(3+) is exploited to separate these elements.

[0011] The Ra-226 containing target comprises either RaCl, Ra(NO), Ra(OH), or RaCO. An advantage of embodiments of the present invention is that different types of Ra-226 containing targets can be used.

[0012] Said irradiation with charged particles comprises irradiation with protons and / or irradiation with deuterons. An advantage of embodiments of the present invention is that both proton and / or deuteron irradiation can be used.

[0013] The method may further include producing Ra-225 isotopes apart from producing at least Ac-225 and Ac-224 isotopes when deuteron irradiation is used.

[0014] Irradiation with charged particles may, in some embodiments, include or involve protons having an incident beam energy of at least 15 MeV, e.g., 15 MeV to 30 MeV, e.g., about 22 MeV, e.g., 18 MeV to 30 MeV, e.g., 18 MeV to 25 MeV.

[0015] Irradiation with charged particles can, in some embodiments, include or be with deuterons. Irradiation with deuterons can be irradiation with deuterons having an incident beam energy of at least 20 MeV, e.g., 20 MeV to 60 MeV, e.g., 20 MeV to 50 MeV, e.g., about 27 MeV.

[0016] An advantage of embodiments of the present invention is that during the production of Ac-225 isotope, the co-production of Ac-224 isotope can be maximized, thus providing the greatest potential for producing Pb-212 isotope, while maintaining sufficient Ac-225 isotope production.

[0017] The irradiation with photons can include irradiation with high-energy photons, such as gamma photons, e.g., photons having an energy of >6.4 MeV. An advantage of embodiments of the present invention is that the production of Ac-225 is relatively clean, in that only small amounts or even no other Ac isotopes are produced. In embodiments, the photons have an energy of >12 MeV, which, in embodiments, is the threshold for the production of Ra-224 / Pb-212.

[0018] After a second further waiting time applied after said first further waiting time, the method may include applying a further extractive chromatography process to further separate the Pb from the remaining fraction containing radium.

[0019] An advantage of embodiments of the present invention is that additional production of the Pb-212 isotope can be obtained due to further decay of radium. This process can be repeated until the amount of Pb-212 is no longer sufficient to cover the processing costs.

[0020] An equivalent of 18-crown-6 ether, in embodiments, can be any compound that has extraction chromatography functionality for Pb equivalent to that of 18-crown-6 ether. An equivalent of 18-crown-6 ether, in embodiments, can be any compound that contains a cyclic chain of carbon and oxygen atoms equivalent to that contained in 18-crown-6 ether.

[0021] An equivalent of 18-crown-6 ether differs from 18-crown-6 ether in that, in embodiments, the equivalent includes one or more substituents on the cyclic chain, which may include heteroatoms on one or more carbon atoms, i.e., saturated or unsaturated hydrocarbons replacing one or more hydrogen atoms of 18-crown-6 ether. In embodiments, the equivalent includes at least one π-bond between two adjacent carbon atoms of the cyclic chain. In embodiments, the equivalent of 18-crown-6 ether includes benzo-18-crown-6 ether or dibenzo-18-crown-6 ether, or an equivalent thereof.

[0022] Separation of Pb from the remaining fraction containing radium can be based on extraction chromatography using Sr or Pb resins in HNO3 and / or HCl. Alternatively, the resin can be any other resin bearing 18-crown-6 ether.

[0023] An advantage of embodiments of the present invention is that the production of Pb-212 can be obtained in a relatively easy manner.

[0024] The irradiation with charged particles may include irradiation with deuterons, and the method further includes separating Ac-225 from the remaining fraction containing radium based on extraction chromatography using DGA.

[0025] The irradiation of the Ra-226-containing target can include irradiation using a single irradiation beam stacked target, the stacked target including a first target for irradiation with charged particles having a first incident beam energy and a second target for irradiation with charged particles having a second incident beam energy, the first incident beam energy being higher than the second beam energy, and the first and second targets being stacked and arranged such that the single irradiation beam first enters the first target and then enters the second target after leaving the first target.

[0026] An advantage of embodiments of the present invention is that by using stacked targets, one target can be optimized for the production of Ac-225 and one target can be optimized for the combined production of Ac-225 and Pb-212.

[0027] Applying extraction chromatography to separate Pb from the remaining fraction containing radium may be feasible for the first target but not for the second target.

[0028] An advantage of embodiments of the present invention is that the second target has a lower amount of Ac-224 present, and therefore less contamination of the Ac-225 isotope, and the Ac-225 isotope is already available after a shorter cooling time.

[0029] The product of the thickness and density of the first target is greater than the product of the thickness and density of the second target.

[0030] The present invention also relates to compounds containing the Pb-212 isotope obtained using the method as described above.

[0031] The compound may contain trace amounts of Pb-210, the concentration as measured by its activity, relative to the activity of Pb-212, may be in the range of 0.00001% to 0.01%, for example, in the range of 0.00005% to 0.01%.

[0032] The present invention also relates to the use of compounds as described above for targeted alpha therapy.

[0033] The present invention also relates to a target assembly for use in the production of Ac-225 and Pb-212 isotopes, the target assembly comprising a stack of a first radium-containing target and a second radium-containing target.

[0034] The present invention also relates to a chromatography system for separating Pb from a radium-containing fraction, the chromatography system being an extractive chromatography system using a resin having 18-crown-6 ether as an extractant in HNO3 and / or HCl. The chromatography system can use either an Sr or Pb resin. The chromatography system can include a DGA resin below the resin having 18-crown-6 ether as an extractant. The present invention further relates to a method for separating Pb from a radium-containing fraction.

[0035] Particular and preferred aspects of the invention are set out in the accompanying independent and dependent claims. Features from the dependent claims may be combined with features of the independent claims and with features of other dependent claims as appropriate and not merely as explicitly set out in the claims.

[0036] These and other aspects of the invention will be apparent from and elucidated with reference to the embodiment(s) described hereinafter. [Brief explanation of the drawings]

[0037] [Figure 1] FIG. 1 shows a cross section of the Ra-226 proton reaction, information that can be used in embodiments according to the present invention. [Figure 2] FIG. 2 shows a cross section of the Ra-226 deuteron reaction, information that can be used in embodiments according to the present invention. [Figure 3] FIG. 3 shows a flow chart for Pb-212 separation from proton irradiation according to an embodiment of the present invention. [Figure 4] FIG. 4 shows a flow chart for Pb-212 separation from deuteron irradiation according to an embodiment of the present invention. [Figure 5]FIG. 5 shows the acid dependence of k′ for actinides and other selected ions at 23° C. to 25° C. for loaded Sr resin particle sizes between 50 μm and 100 μm, as can be used in embodiments according to the present invention. [Figure 6] FIG. 6 shows the acid dependence of k′ for alkaline earth metal ions at 23° C. to 25° C. for loaded resin particle sizes between 50 μm and 100 μm, as can be used in embodiments according to the present invention. [Figure 7] FIG. 7 shows the retention factor k′ for Ra(II) and Pb(II) in HCl for a loaded Sr resin as can be used in an embodiment according to the present invention. [Figure 8] FIG. 8 shows the k' factor for selected transition and post-transition elements for TODGA resin (50 μm and 100 μm) versus HNO for a 1 hour equilibration period at 22° C., as may be used in embodiments according to the present invention. [Figure 9] FIG. 9 shows the dependence of Kd values ​​of Ac in various Sr resin / acid systems on acid concentration, as can be used in embodiments according to the present invention. [Figure 10] FIG. 10 shows the k′ factors for AC-225 versus [HNO 3 ] or HCl on DGA resin as may be used in embodiments according to the present invention. [Figure 11] FIG. 11 shows an example of a stacked target assembly, according to an embodiment of the present invention. [Figure 12] FIG. 12 shows PB-212 as a function of decay time, providing information that can be used in embodiments of the present invention. [Figure 13] FIG. 13 shows the decay of 5 kBq of Ra-224, providing information that can be used in embodiments of the present invention. [Figure 14] FIG. 14 shows the attenuation of 1.5 MBq of Ra-225, providing information that can be used in embodiments of the present invention. [Figure 15] FIG. 15 shows a cross section of the Ra-226 photon response, information that can be used in embodiments according to the present invention.

[0038] The drawings are only schematic and non-limiting. In the drawings, the size of some of the elements may be exaggerated and not drawn to scale for illustrative purposes.

[0039] Any reference signs in the claims should not be construed as limiting the scope.

[0040] In the different drawings, the same reference signs refer to the same or similar elements. DETAILED DESCRIPTION OF THE INVENTION

[0041] The present invention will be described with respect to particular embodiments and with reference to certain drawings but the invention is not limited thereto but only by the claims. The drawings described are merely schematic and are non-limiting. In the drawings, the size of some of the elements may be exaggerated and not drawn to scale for illustrative purposes. The dimensions and relative dimensions do not correspond to actual reduction to practice of the invention.

[0042] Furthermore, the terms first, second, etc. in the specification and claims are used to distinguish between similar elements and are not necessarily used to describe any order, temporal or spatial, in ranking or in any other way. It is understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments of the invention described herein are capable of operating in sequences other than those described or illustrated herein.

[0043] Furthermore, terms such as up, down, and the like in the specification and claims are used for descriptive purposes and not necessarily to describe relative positions, and it is understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments of the invention described herein are capable of operation in orientations other than those described or shown herein.

[0044] It should be noted that the term "comprising" used in the claims should not be interpreted as limiting the meaning of the enumerated items thereafter; it does not exclude other elements or steps. Thus, it is interpreted as specifying the presence of a stated feature, a recited integer, a step, or a component, but does not exclude the presence or addition of one or more other features, integers, steps, or components, or groups thereof. Thus, the scope of the expression "a device comprising means A and B" should not be limited to a device consisting only of components A and B. It means that, in the context of the present invention, the only relevant components of the device are A and B.

[0045] References throughout this specification to "one embodiment" or "an embodiment" mean that a particular feature, structure, or characteristic described in connection with an embodiment is included in at least one embodiment of the present invention. Thus, the appearances of the phrases "in one embodiment" or "in an embodiment" in various places throughout this specification do not necessarily refer to the same embodiment, although they may. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner, as would be apparent to one of ordinary skill in the art from this disclosure, in one or more embodiments.

[0046] Similarly, in describing representative embodiments of the present invention, it should be understood that various features of the invention may be grouped together in a single embodiment, drawing, or description thereof for the purpose of streamlining the disclosure and aiding in understanding one or more of the various inventive aspects. This method of disclosure, however, should not be interpreted as reflecting an intention that the claimed invention requires more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive aspects lie in less than all features of a single previously disclosed embodiment. Accordingly, the claims following the detailed description are hereby expressly incorporated into this detailed description, with each claim standing on its own as a separate embodiment of the present invention.

[0047] Furthermore, while some embodiments described herein include some features but not others included in other embodiments, it is meant that combinations of features from different embodiments are within the scope of the present invention and form different embodiments, as would be understood by one of ordinary skill in the art. For example, in the following claims, any of the claimed embodiments can be used in any combination.

[0048] In embodiments of the present invention, when reference is made to the thickness of a target, this may typically be expressed not just as the physical thickness itself but as the multiplication of the physical thickness multiplied by the density. Thus, thickness is expressed in g / cm 2 It may be expressed as

[0049] In the description provided herein, many specific details are set forth. However, it is understood that embodiments of the present invention can be practiced without these specific details. In other instances, well-known methods, structures, and techniques have not been shown in detail so as not to obscure an understanding of this description. A method for producing Pb-212 and Ac-225 isotopes is described. Apart from these isotopes, production of Ra-225 isotopes can also be anticipated, depending on the charged particles and / or photons used. These isotopes can be advantageously used for medical applications. The method includes irradiating a Ra-226-containing target with charged particles and / or photons to produce at least Ac-225 and Ac-224 isotopes, and optionally Ra-225. The Ra-226-containing target may include, for example, any of RaCl2, Ra(NO3)2, Ra(OH)2, or RaCO3.

[0050] In some embodiments, irradiation with charged particles can be irradiation with protons. When Ra-226 (with a half-life T of 1600 years) is irradiated with low-energy (10-25 MeV) protons, Ac-225 (with a half-life T of 10 days) is formed in the Ra-226(p,2n)Ac-225 nuclear reaction. At approximately 14 MeV, the threshold energy for another reaction, the (p,3n) reaction, is reached, resulting in the production of Ac-224 (with a half-life T of 2.9 hours), which rapidly decays to Ra-224 (with a half-life T of 3.66 days). Above an energy of 17 MeV, the (p,3n) reaction becomes dominant, but Ac-225 is still produced in significant quantities. The figure shows a cross section of the Ra-226 proton reaction. Depending on the type of proton accelerator used and the maximum proton energy it can provide, the beam passing through the target can be shaped for different optimizations: in one embodiment, Ac-224 production can be optimized (Ra-224 / Pb-212) by selecting an energy in the range of, for example, 25 MeV → 15 MeV. In another embodiment, Ac-225 production with minimal Ac-224 / Ra-224 can be obtained by selecting an energy in the range of, for example, 17 MeV → 10 MeV. In yet another embodiment, high production of both Ac-225 and Ac-224 / Ra-224 can be obtained by selecting an energy in the range of, for example, 25 MeV → 10 MeV.

[0051] In some embodiments, irradiation with charged particles can be irradiation with deuterons. Irradiation of Ra-226 with deuterons (D) instead of protons (H) can produce even larger amounts of Ac-225 and Pb-212. A Ra-226 deuteron reaction cross section is shown in Figure 2. The advantages of using deuterons instead of protons are a higher cross section, extended range at the target at high energies, and significant co-production of Ra-225 and Ra-224, which can significantly increase production capacity. Depending on the type of deuteron accelerator used and the maximum deuteron energy it can provide, the beam through the target can be shaped for different situations. In one embodiment, Ac-224 (Ra-224 / Pb-212) production can be optimized by selecting an energy in the range of, for example, 60 MeV to 15 MeV. In another embodiment, Ac-225 production with minimal Ac-227 / Ac-224 / Ra-224 production can be obtained by selecting an energy in the range of, for example, 20 MeV to 10 MeV. In yet another embodiment, high production of both Ac-225 and Ac-224 / Ra-224 can be obtained by selecting an energy in the range of 60 MeV → 10 MeV.

[0052] One aspect of deuteron irradiation is that the production of Ac-226 (T1 / 2: 29 hours) is even more significant than with protons. Ac-226 also has interesting properties used for the TAT, 83% beta decay to Th-226 (a short-lived alpha emitter (4α's)), and 17% electron capture decay to Ra-226. For a hypothetical therapeutic Ac-225 dose of 200 μCi, combined with 10% activity of Ac-226 (20 μCi), a total of 0.25 Bq of Ra-226 and 93 Bq of Pb-210 are produced from the decay of Ac-226. With an annual intake limit (ALI) for intake of 71 kBq for Ra-226 and 29 kBq for Pb-210 (source: nucleonica.com), this co-produced Ra-226 and Pb-210 is not expected to pose a problem for clinical applications.

[0053] Irradiation with photons, in embodiments, includes irradiation with high-energy photons, such as gamma photons having an energy of at least 6 MeV. In certain embodiments, photons having an energy of at least 6 MeV are preferred for converting Ra-226 to Ra-225, which subsequently decays to Ac-225. In embodiments, an advantage of using photons is that it may be the cleanest method of producing Ac-225, since no other Ac isotopes are produced. In embodiments, production of Ra-224 may be significant when using photons having an energy greater than 12 MeV.

[0054] In embodiments, the photon cross section of the (γ,n) reaction to produce Ra-225 is relatively low. This problem can be solved by using a high photon flux, for example, when amounts of Ac-225 above 1 Ci are desired: for example, a 20-40 MeV electron accelerator can be used in combination with a high-power electron converter to produce the bremsstrahlung photons required for this reaction. Advantageously, due to the lack of charge of photons, the range, i.e., the penetration depth of photons into the target, can be even greater than with charged particles. Therefore, advantageously, when photons are used, the target mass can be up to 10 g of Ra-226 or more. In embodiments, the higher the energy of the electrons striking the converter, the more photons there are above the 12 MeV threshold for the production of Ra-224 / Pb-212. The energy of the electrons striking the converter, which determines the photon flux above 12 MeV, can be fine-tuned to increase or decrease the co-produced Ra-224.

[0055] Liquid targets can also be used for the Ra-226(γ,n)Ra-225 production pathway, as the high-energy photon flux is not strongly affected by the presence of HO. In embodiments, the properties, e.g., shape and / or flux of the photon beam, can be largely determined by the electronic converter, which defines the optimal Ra-226 target.

[0056] The method also includes applying chromatography to separate actinium from the remaining fraction containing radium after the cooling period. The chromatography step can be extraction chromatography, but can alternatively be ion exchange chromatography using a cation exchange column. In ion exchange chromatography, the difference in charge between Ra(2+) and Ac(3+) is utilized to separate these elements. The method further includes applying extraction chromatography to separate Pb from the remaining fraction containing radium after a first additional waiting period. In the method, a resin having 18-crown-6 ether or an equivalent of 18-crown-6 ether is used as an extractant in HNO3 and / or HCl.

[0057] As an illustration, a representative flow chart for separating Pb-212 using proton irradiation is shown in Figure 3. As a simplified theoretical example, a single 100 mCi Ra-226 target was irradiated with protons from 22 MeV to 10 MeV, producing 100 mCi Ac-225 and 8276 mCi Ac-224 at EOB (post-bombardment), which are equivalent amounts of Ac-224 and Ac-225 atoms. This starting point appears realistic based on a comparison of the calculated yield for Ac-225 and the cross-section data in Figure 1. In this example, after 24 hours of cooling time, 93.3 mCi of Ac-225 tends to separate from Ra. 20.8 mCi of Ac-224 remains present after 24 hours, at 1 / 400 of its original activity. The isotopic purity of Ac-225 on an atomic basis is >99.7%. It still seems reasonable to wait a little longer to purify Ac-225 until the Ac-225 / Ac-224 activity ratio is high enough. In 36 hours, it amounts to 90.1 mCi of Ac-225 and 1 mCi of Ac-224 (an Ac-225 / Ac-224 ratio of 90.1). After 24 hours of cooling, 204 mCi of Ra-224 is formed in the target by decay of Ac-224. The target is opened and the contents are separated into Ac and Ra fractions by extraction chromatography and, optionally, a prior precipitation step. The Ac fraction is removed from the hot cell. The Ra fraction, containing 204 mCi of Ra-224 and 100 mCi of Ra-226, is again stored for 24 hours. Again, after 24 hours (i.e., 48 hours post-EOB), the Ra fraction contained 0.169 Ci of Ra-224 and 0.143 Ci of Pb-212. Decay of Ra-226 produced 0.66 μCi of Pb-210 (T1 / 2: 22.2 years) and 16.1 mCi of Pb-214 (T1 / 2: 26.8 minutes). Extraction chromatography was used to separate the Pb from Ra. After 12 hours (e.g., diffusion, transport to the hospital), the total activity associated with Pb-214 was converted to 40.4 nCi of Pb-210, while 65.4 mCi of Pb-212 remained available, including the presence of 0.66 μCi of Pb-210.For reference, a phase 1 trial of Pb-212-TCMC-trastuzumab showed a maximum of 21.1MBq / m. 2 The dose was tested at an average body surface area of ​​1.7 m 2 67 patient doses can be prepared from this 65.4 mCi of Pb-212. The Ra fraction is again stored for 24 hours. Next (72 hours after EOB), 0.140 Ci of Ra-224 remains and 119 mCi of Pb-212 can be separated. Following the same route, this will result in 56 patient doses. This process can be repeated until the amount of Pb-212 is no longer high enough to cover the process costs.

[0058] The same method can be applied to deuteron irradiation. The first target in the beam can be used to produce primarily Ac-224, while the second target produces primarily Ac-225. However, compared to proton irradiation, the cross-section for the production of Ra-224 and Ra-225 is more pronounced, and Ac-225 can be produced from Ra-225, increasing the complexity of the separation process. As an illustration, a representative flowchart for separating Pb-212 using deuteron irradiation is shown in Figure 4. As a simplified theoretical example, a single 500 mCi Ra-226 target irradiated with deuterons at 50 MeV → 10 MeV produced 1 Ci of Ac-225 and 165.52 Ci of Ac-224 at EOB (after bombardment), which is more than twice as much Ac-224 as Ac-225 atoms. 338 mCi of Ra-225 is produced, half the amount of Ac-225 atoms, and 683 mCi of Ra-224 is produced, half the amount of Ra-225 atoms. After 24 hours of cooling time, 933 mCi of Ac-225 + 22.1 mCi of Ac-225 from the decay of Ra-225 tend to separate from Ra. 417 mCi of Ac-224 remains present after 24 hours, at 1 / 400 of its original activity. The isotopic purity of Ac-225 on an atomic basis is >99.5%. It still seems reasonable to wait a little longer to purify Ac-225 until the Ac-225 / Ac-224 activity ratio is sufficiently high. At 36 hours, it amounts to 923 mCi of Ac-225 and 20.9 mCi of Ac-224 (an Ac-225 / Ac-224 ratio of 44.2).

[0059] After 24 hours of cooling, 4.08 Ci of Ra-224 was formed in the target from the decay of Ac-224, and 0.565 Ci of Ra-224 was still present from direct production. The target was opened, and the contents were separated into Ac and Ra fractions by extraction chromatography and, optionally, a preliminary precipitation step. The Ac fraction was removed from the hot cell. The Ra fraction, containing 4.645 Ci of Ra-224, 323 mCi of Ra-225, and 500 mCi of Ra-226, was again stored for 24 hours. After 24 hours (i.e., 48 hours after EOB), the Ra fraction contained 3.84 Ci of Ra-224 and 3.26 Ci of Pb-212. The decay of Ra-225 produced 21.1 mCi of Ac-225. Decay of Ra-226 produced 3.3 μCi of Pb-210 (T1 / 2: 22.2 years) and 80.5 mCi of Pb-214 (T1 / 2: 26.8 min). Extraction chromatography was used to separate Pb from Ac and Ra. After 12 hours (e.g., diffusion, transport to the hospital), the total activity associated with Pb-214 was converted to 202 nCi of Pb-210, while 1.49 Ci of Pb-212 remained available, including the presence of 3.3 μCi of Pb-210. As a reference, a phase 1 study of Pb-212-TCMC-trastuzumab demonstrated a maximum activity of 21.1 MBq / m 2 The dose was tested at an average body surface area of ​​1.7 m 2 Approximately 1,500 patient doses can be prepared from this 1.49 Ci of Pb-212. The Ra fraction is again stored for 24 hours. Next (72 hours after EOB), 3.17 Ci of Ra-224 remains, and 2.7 Ci of Pb-212 can be separated. Following the same route, this yields approximately 1,250 patient doses. Also, 20.1 mCi of Ac-225 is produced from the decay of Ra-225. This process can be repeated until the amount of Pb-212 is no longer high enough to cover the process costs. Thereafter, it may still be an option to store the Ra fraction for final Ac-225 recovery, for example, two to three weeks after EOB. A major advantage of obtaining the Ac-225 fraction from the Ra-225 fraction is the absence of Ac-224, Ac-226, and Ac-227 contaminants.

[0060] As an illustration of an embodiment in which irradiation is performed using photons, see FIG. 15, which shows a cross-section of the photon reaction of Ra-226 to form Ra-225, Ra-224, and Ra-223 as a function of photon energy. For photon energies between 6 MeV and 12 MeV, primarily Ra-225 is produced. A photon energy of 12 MeV is the threshold for the production of Ra-224. A photon energy of 19 MeV is the threshold for the production of Ra-223. In one example, one gram of Ra-226 is irradiated with photons for 48 hours. In this example, it is assumed that for every 10 Ac-225 atoms produced, one atom of Ra-224 is simultaneously produced, i.e., corresponding to photon energies of 11 MeV to 12 MeV. After end of irradiation (EOI), a one-day cooling period is performed before a first separation is performed, i.e., Ra, Ac, and Pb are separated from each other, according to an embodiment of the present method. In an embodiment, the same separation method can be followed as for deuteron irradiated targets. In this example, further separations are also performed every 48 hours after the previous separation. Activity for different isotopes before and after subsequent separations is summarized in Table 1: Five separations are performed, and for each separation, the number of days after EOI is mentioned.

[0061] [Table 1]

[0062] In this specification, each box in the table corresponding to one of the separations contains two rows for each isotope contained in the target: the upper row corresponds to the isotope contained in the target before the corresponding separation, and the lower row corresponds to the isotope contained in the target after the corresponding separation, i.e., after extraction of the corresponding amount of Ac and Pb from the target. In this example, the first Ac fraction extracted during the first separation may be contaminated with a small amount of Ac-227, i.e., 0.1 mCi in this example. Perhaps the first Ac fraction is only suitable for the Ac-225 / Bi-213 generator. In the second separation, 589 mCi of Ac-225 may be extracted; in the third separation, 759 mCi; in the fourth separation, 1220 mCi; and in the fifth, 1010 mCi. In this example, five separations are performed, but more can be performed to collect more Ac-225.

[0063] The first Pb fraction in this example may also contain larger amounts of Pb-210 and Pb-214 compared to the successive Pb fractions (not shown in Table 1). However, as shown by this example, 1200 mCi of Pb-212 may be extracted in the second separation, 823 mCi in the third separation, and 232 mCi in the fourth separation. Therefore, even if the first fraction is ignored, the Ci amount of Pb-212 can be obtained in this example.

[0064] An example of chemical separation of Pb from Ra is further considered. Separation of Pb from Ra is straightforward, for example, using Sr (or Pb) resin. Because Pb has a high affinity for 18-crown-6 crown ether on Sr resin in HNO, the Ra fraction can be loaded over a wide concentration range, from dilute to 2-4 M HNO, limited primarily by the solubility of Ra(NO) (see Figure 5). Sr resin has no affinity for Ra in HNO (see Figure 6). It is also possible to load Sr resin in an HCl matrix. In one embodiment, the HCl matrix can be 1 M to 2 M HCl (as can be seen in Figure 7). The lack of affinity for Ra was observed over the entire concentration range. Stripping of Pb from Sr resin by forming a Pb-lead chloride complex can be efficiently performed using 8 M HCl, leaving Po-210 on the resin. Alternatively, 0.1 M ammonium citrate, 0.1 M ammonium oxalate or 0.1 M glycine can also be used to recover Pb from Sr resin.

[0065] An example of chemical separation of Ac from Pb / Ra using a tandem with DGA is also considered. If Ra-225 is present when irradiating Ra-226 with deuterons, the DGA resin can be placed in series with the Sr resin, and increased Ac-225 can be obtained from the DGA. Because Pb is somewhat retained by the DGA (see Figure 8), and Ac is not retained by the Sr resin in the HNO3 or HCl matrix (see Figure 9), the DGA needs to be placed below the Sr. Ac-225 can be eluted using dilute HCl or dilute HNO3.

[0066] According to embodiments of the present invention, the method as described above can utilize a stacked target assembly. In such a stacked target assembly, two or optionally more targets are stacked so that they can be used simultaneously in a single irradiation session for the production of Ac-225 and Pb-212 isotopes. The target assembly includes a stack of a first radium-containing target and a second radium-containing target. The first target of the beam can be adapted to produce primarily Ac-224 → Ra-224, while the second target, which enters after the radiation beam has passed through the first target, produces primarily Ac-225.

[0067] As an example, using a RaCl2 target and an incident beam energy of 25 MeV, (1.51~0.793) 0.717 g / cm 2 The target is placed in the beam as the first target, where the beam exits this target at 17 MeV. Then, 2 A target of 10 MeV was stacked directly behind it, where the beam exited at 10 MeV. In this way, optimization of isotope production was obtained. An example of stacked targets is shown in Figure 11.

[0068] A similar example can be given for deuteron irradiation. The first target of the beam can be used to produce primarily Ac-224, while the second target produces primarily Ac-225. The cross sections for Ra-224 and Ra-225 production are more pronounced for deuteron irradiation compared to proton irradiation. Based on the data shown in Figure 2, in one example, deuterons at 50 MeV on the first target produce primarily Ac-224 until about 22 MeV, at which point Ac-225 production becomes dominant. Ra-225 and Ra-224 are primarily produced within the first target. As an example, using a RaCl2 target and an incident beam energy of 50 MeV, the Ra-225 and Ra-224 concentrations are (3.062 - 0.97) 2.092 g / cm3. 2 The target is placed in the beam as the first target, where the beam exits this target at 25 MeV. Then, 2The target is stacked directly behind it, where the beam exits at 10 MeV. Thus, optimization of isotope production is possible.

[0069] The Ac-225 produced from the first target has a higher amount of Ac-227 and may be suitable only for the production of an Ac-225 / Bi-213 generator.

[0070] [Table 2]

[0071] By way of illustration, and not limitation, examples of experimental results are now discussed below to demonstrate features and advantages of embodiments of the present invention.

[0072] In the first example, proton irradiation of RaCl2 is considered. Using modeling software, the projected range of the protons is theoretically evaluated, and the results are shown in Table 2.

[0073] The thickness of the target material is expressed as g / cm 2 (thickness multiplied by density). If the density of RaCl2 is 2 g / cc, the projected range of a 25 MeV proton in RaCl2 is 1.51 g / cm 2 / 2g / cm 3 = 0.755 cm. As can be seen in Figure 1, below 10 MeV there is no further significant production of Ac-225, while the protons still release their energy as heat within the target (1.6 x 10-12 J / proton). Therefore, according to an embodiment of the present invention, the target is adjusted to the appropriate energy range so that the protons exit the target material at approximately 10 MeV. For a 25 MeV RaCl2 target, this is 1.51 - 0.332 = 1.178 g / cm 2 , or 0.589 cm for a 2 g / cc target.

[0074] In the second example, deuteron irradiation of RaCl2 is considered. Using modeling software, the projected range of the deuterons is theoretically evaluated, and the results are shown in Table 3.

[0075] [Table 3]

[0076] Comparing the range data for protons (Table 2) and deuterons (Table 3), it is clear that the range of deuterons at a particular energy is significantly lower than the corresponding range of protons, but the higher cross section at higher energies (see Figure 2) results in higher obtainable yields that compensate for the above effects.

[0077] In the third example, proton irradiation was studied on surrogate targets including Ra(NO3)2, Ra(OH)2 (electroplating), and RaCO3. The proton ranges for these compounds are shown in Table 4.

[0078] [Table 4]

[0079] The difference in range between the compounds is fairly limited, and for deuterons there are no significant differences between the compounds.

[0080] In the following example, a complete experiment for isotope derivation is considered. A source of purified Th-229 available from historical Th-228 (T1 / 2: 1.913 years) production, in which a small amount of original Th-228 is present (approximately 15 kBq), is used to produce Ac-225. During this separation process, Ra-225 is also collected separately. As Th-228 decays through Ra-224, the Ra-224 activity is in equilibrium with Th-228 activity at the point of the Th / Ac / Ra separation and is collected in the same fraction as Ra-225. This radium fraction is the starting solution for the experiment.

[0081] After Th-229 / Ra-225 / Ac-225 separation of approximately 6.3 MBq of Th229 source, the Ra fraction (approximately 40 ml-45 ml) in 4 M HNO3 matrix was further processed by extraction chromatography using a Triske vacuum box.

[0082] In the first step, initial recovery of Pb-212 and Ac-225 was performed. After approximately 24 hours, a 1 ml sample from the Ra fraction was taken for HPGe analysis to verify Ra-225 activity and obtain Ra-225 / Ac-225 and Ra-224 / Pb-212 equilibrium parameters (Pb S1). A 2 ml Sr cartridge and a 2 ml DGA cartridge in series (Sr under DGA) were pretreated with 10 ml of 4 M HNO3. Next, 10 ml (5 BV) of the Ra fraction was loaded onto the column. Pb-212 was retained by the Sr resin. Ac-225 passed through the Sr resin but was retained by the DGA resin. Ra-225 / Ra-224 passed through both resins. The Sr resin was rinsed with 10 ml (5 BV) of 1 M HNO3.

[0083] Pb and Ac were quantitatively retained by the Sr and DGA resins. Because the k's for Ac and Pb on each DGA and Sr resin were still sufficiently high, 1 M HNO3 was chosen instead of 4 M. This lower HNO3 concentration allowed fractions to be evaporated / distilled back to their original volume (or close to it) without increasing the acid concentration too much. This could be important when the solubility of Ra in HNO3 is involved. A total of 20 ml was collected (Pb S2). The DGA was removed from under the Sr resin. Pb-212 was eluted from the Sr resin using 10 ml of 8 M HCl (Pb S3). Another 10 ml of 8 M HCl was added to the Sr resin to verify tailing (Pb S4). Ac-225 was eluted from the DGA using 10 ml of 0.1 M HCl (Pb S5).

[0084] In the second step, a second recovery of Pb-212 and Ac-225 was performed. 24 h after the initial Pb / Ac / Ra separation, the process described above was repeated, starting directly from the Ra fraction of the first part, Pb S2 (10 ml of 4 M HNO3 + 10 ml of 1 M HNO3). A 2 ml Sr cartridge and a 2 ml DGA cartridge in series (DGA below Sr) were pretreated with 10 ml of 4 M HNO3.

[0085] Next, 20 ml (10 BV) of Pb S2 was loaded onto the column. Pb-212 was retained by the Sr resin. Ac-225 passed through the Sr resin but was retained by the DGA resin. Ra-225 / Ra-224 passed through both resins. The Sr resin was rinsed with 10 ml (5 BV) of 1 M HNO3. Pb and Ac were quantitatively retained by the Sr and DGA resins. A total of 30 ml was collected. The DGA was removed from under the Sr resin. Pb-212 was eluted from the Sr resin with 10 ml of 8 M HCl (Pb S6). Another 10 ml of 8 M HCl was added to the Sr resin to verify tailing (Pb S7). Ac-225 was eluted from the DGA with 10 ml of 0.1 M HCl (Pb S8).

[0086] To interpret the above example, consider the decay of Pb-212 activity as a function of time. When Pb-212 is separated from Ra-224 and Ac-225, Pb-212 production from Ra-224 ceases, and the decay of Pb-212 reduces its activity. For example, after 5 hours of measurement, the remaining Pb-212 activity is only 72% of the activity from the start of the measurement. The decay as a function of decay time is shown in Figure 12.

[0087] Furthermore, the Pb-212 and Ac-225 that have increased in the Ra (224 + 225) fraction are also taken into account. Once the Pb / Ac / Ra separation is performed and the Ra fraction is collected, Pb-212 and Ac-225 / Bi-213 begin to increase internally. Figures 13 and 14 show the rate of increase internally. For this reason, trace amounts of Pb-212 and Ac-225 that have passed through the Sr and DGA resin cannot be detected because they are immediately hidden by the newly produced Pb-212 and Ac-225.

[0088] The results from gamma spectroscopy without attenuation and ingrowth correction are shown in the table below.

[0089] [Table 5]

[0090] [Table 6]

[0091] The first Pb fractions (S3 and S6), separated from Ra and Ac, collect Pb-212 in 5 BV of 8 M HCl. Rinsing of the feed column and cartridge is performed with 5 BV of 1 M HNO3 only, so traces of Ra-225 are still present in the Pb fractions. For both S3 and S6, this is approximately 0.08%, or >10 3 of DFRa. Rinsing the Sr-resin with an additional 5-10 BV of 1-4 M HNO3 can be performed without breakthrough of Pb-212, presumably due to the very high k'Pb in this acid matrix (see Figure 12), further increasing DFRa. It has been shown that 8 M HCl can be used to recover Pb from Sr-resin, but (complexing) alternatives such as citric acid and oxalic acid can also be used for this purpose.

[0092] The second Pb fraction (S4 and S7) contains almost no residual Pb-212 and traces of Ra. This indicates that the recovery of Pb-212 in 5 BV of 8 M HCl (S3 and S6) is nearly quantitative. The Ra fraction (S2) recovers almost all of the Ra. The activity of Ac-225 (Bi-213) and Pb-212 is explained by the internal enrichment from Ra-225 / Fr-221 and Ra-224.

[0093] The Ac fractions (S5 and S8) from the DGA collect and recover Ac as expected, but no Pb is identified in this fraction. As with the Pb fraction, a small amount of BV to rinse the column and cartridge results in visible traces of Ra in this fraction. For S5, this is 0.04%, and for S8, this is 0.05%. Experience has shown that DGA can be rinsed with 10 BV of 1-4 M HNO3 without detectable Ac breakthrough, and these rinses further increase DFRa.

[0094] Furthermore, there is no indication that the process performed in Part 2 is less effective than Part 1. Ac-225 is collected in approximately the same amount. Ra-225 decay after one day is only 4.6%, and Ac-225 decay after collection and during measurement is less pronounced. Pb-212 measurement activity is highly dependent on collection and measurement times. If Ac-225 production is pursued, coproduced Ac-224 / Ra-224 / Pb-212 can still be valued without significant additional effort. Therefore, Ac-224 coproduction is not necessarily considered a negative aspect when producing Ac-225. The proton / deuteron energy entering the target is adaptable and can be optimized for maximum Ac-225 production, minimized Ac-224 production, or maximized production of both. Stacked target designs can improve processing efficiency.

[0095] If the radium fraction after the first Ra / Ac separation is further processed, Ac-225 and / or Pb-212 can be separated multiple times. In particular, in the case of deuteron irradiation, Ra-224 and Ra-225 will be valuable sources of Pb-212 and NCA Ac-225. Based on the serial Sr resin and DGA, this process can be repeated several times to produce the desired nuclei.

Claims

1. 1. A method for producing Pb-212 and Ac-225 isotopes, comprising: - irradiating a Ra-226 containing target with charged particles and / or photons to produce at least Ac-225 and Ac-224 isotopes; - after a first cooling time, applying a first chromatography to separate actinium from the remaining fraction containing radium, and After a second waiting period, HNO was added to separate the Pb from the remaining fraction containing radium. ３ and / or applying a second extraction chromatography using a resin with 18-crown-6 ether or an equivalent of 18-crown-6 ether as the extractant in HCl. A method comprising:

2. 2. The method of claim 1, wherein the Ra-226-containing target comprises any of RaCl2, Ra(NO3)2, Ra(OH)2, or RaCO3.

3. 3. The method according to claim 1, wherein said irradiation with charged particles comprises irradiation with protons and / or irradiation with deuterons.

4. said irradiation with charged particles comprising: - irradiation with protons having an incident beam energy of at least 18 MeV, or - irradiation with deuterons having an incident beam energy of at least 20 MeV. The method of claim 3, comprising:

5. 5. The method of claim 1, further comprising applying a third extraction chromatography process applied after a third waiting time following the second extraction chromatography, the third extraction chromatography process being for further separating Pb from a remaining fraction containing radium.

6. In the third extraction chromatography, HNO ３ and / or a resin having 18-crown-6 ether as an extractant in HCl.

7. 7. The method of claim 1, wherein the irradiation with charged particles comprises irradiation with deuterons and the first chromatography uses DGA as the extractant.

8. 8. The method of any one of claims 1 to 7, wherein the irradiation of the Ra-226-containing target comprises irradiation using a single irradiation beam stacked target, the stacked target comprising a first target for irradiation with charged particles having a first incident beam energy and a second target for irradiation with charged particles having a second incident beam energy, the first incident beam energy being higher than the second beam energy, and the first and second targets being stacked and arranged such that the single irradiation beam first enters the first target and leaves the first target before entering the second target.

9. 9. The method of claim 8, wherein applying extraction chromatography to separate Pb from the remaining fraction containing radium is performed for the first target but not for the second target.

10. 10. The method of claim 1, wherein the product of thickness and density of the first target is greater than the product of thickness and density of the second target.

11. 1. A method for obtaining a compound containing Pb-212 isotopes and Pb-210, comprising:

11. The method of any one of claims 1 to 10, wherein the concentration of Pb-210, measured by its activity, relative to the activity of Pb-212, is in the range of 0.00001% to 0.01%.

12. 12. The method of claim 11, wherein the compound is for targeted alpha therapy.

13. 1. A target assembly for use in the production of Ac-225 and Pb-212 isotopes, comprising a stack of a first radium-containing target and a second radium-containing target, wherein the product of thickness and density of the first target is greater than the product of thickness and density of the second target.

Images